Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison

被引：2
|
作者：
Levy, Moshe Yair [1 ]
McGarry, Lisa J. [2 ]
Huang, Hui [2 ]
Lustgarten, Stephanie [2 ]
Nieset, Christopher [2 ]
Haluska, Frank G. [2 ]
机构：
[1] Baylor Univ, Med Ctr, Dallas, TX USA
[2] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3154.3154
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] 4-Year Results With Ponatinib by Mutation Status in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML): OPTIC Study
    Deininger, Michael
    Apperley, Jane
    Arthur, Christopher Kevin
    Chuah, Charles
    Hochhaus, Andreas
    de Lavallade, Hugues
    Lipton, Jeffrey
    Lomaia, Elza
    McCloskey, James
    Maness, Lori
    Mauro, Michael
    Moiraghi, Beatriz
    Pavlovsky, Carolina
    Rosti, Gianantonio
    Rousselot, Philippe
    Sutton, Maria Undurraga
    Ren, Xiaowei
    Vorog, Alexander
    Kantarjian, Hagop
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S353 - S354
  • [42] Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI)
    Sasaki, Koji
    Kantarjian, Hagop M.
    O'Brien, Susan M.
    Ravandi, Farhad
    Konopleva, Marina
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Wierda, William G.
    Daver, Naval
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Jain, Preetesh
    Rios, Mary B.
    Pierce, Sherry
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [43] Does the Achievement of MR4.5 Improve the Outcome of Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Front Line Tyrosine Kinase Inhibitors (TKI)?
    Falchi, Lorenzo
    Kantarjian, Hagop M.
    Wang, Xuemei
    Jabbour, Elias
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Kadia, Tapan
    Pemmaraju, Naveen
    Ferrajoli, Alessandra
    Daver, Naval
    Dellasala, Sara Emogene
    Pierce, Sherry
    Verstovsek, Srdan
    Cortes, Jorge E.
    BLOOD, 2015, 126 (23)
  • [44] Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study
    Gjertsen, Bjorn T.
    Hochhaus, Andreas
    Rosti, Gianantonio
    Watts, Justin M.
    Orti, Guillermo
    le Coutre, Philipp
    Leip, Eric
    Viqueira, Andrea
    Cortes, Jorge E.
    Giles, Frank
    Gambacorti-Passerini, Carlo
    BLOOD, 2019, 134
  • [45] Does platelet aggregation differ among chronic myeloid leukemia-chronic phase (CML-CP) patients on tyrosine kinase inhibitors (TKIs)? A tertiary center experience
    Moeen, Sawsan M.
    Afifi, Ola A.
    Thabet, Ahmad F.
    Saleh, Medhat A.
    Morad, Mohamed A.
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2023, 48 (02): : 185 - 190
  • [46] Echocardiographic Findings in Patients (pts) Receiving Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Chronic Myeloid Leukemia (CML)
    Gurguis, Christopher
    de Armas, Lizette Rodriguez
    Kantarjian, Hagop M.
    Boddu, Prajwal C.
    Jain, Preetesh
    Borthakur, Gautam
    Giza, Dana Elena
    Iliescu, Gloria
    Lopez-Mattei, Juan
    Kim, Peter
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Wierda, William G.
    Kornblau, Steven
    Jabbour, Elias J.
    Iliescu, Cezar
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [47] IMPACT OF TYROSINE KINASE INHIBITORS (TKIS) ON THE FERTILITY OF CHRONIC MYELOID LEUKEMIA PATIENTS (CML) IN A SINGLE CENTER IN ALGERIA
    Yamina, B.
    Souad, T.
    Tayeb, A. Mohand
    HAEMATOLOGICA, 2015, 100 : 690 - 691
  • [48] Cause of Death in Resistant and Advanced Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs).
    McGarry, Lisa J.
    Burudpakdee, Chakkarin
    Gala, Smeet
    Seetasith, Arpamas
    Nanavaty, Merena
    Huang, Hui
    BLOOD, 2014, 124 (21)
  • [49] A Real-World Assessment of Hepatic Dysfunction Among Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Receiving First-Line (1L) Tyrosine Kinase Inhibitors (TKIs) in the United States
    Kolibaba, Kathryn
    Zhou, Jie
    Keating, Scott Justin
    Clark, Jamyia
    Brokars, John
    Kee, Arianna
    Copher, Ronda
    Stwalley, Brian
    Jabbour, Elias
    BLOOD, 2020, 136
  • [50] MINIMUM FOLLOW-UP OF 4 YEARS FOR ONGOING PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN A PHASE 1 TRIAL OF PONATINIB
    Talpaz, M.
    Cortes, J. E.
    Kantarjian, H. M.
    Shah, N. P.
    Bixby, D. L.
    Flinn, I. W.
    O'Hare, T. J.
    Hu, S.
    Rivera, V. M.
    Clackson, T.
    Conlan, M. G.
    Haluska, F. G.
    Druker, B. J.
    Deininger, M. W.
    Mauro, M. J.
    HAEMATOLOGICA, 2015, 100 : 65 - 66
12345